These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

613 related items for PubMed ID: 11904969

  • 1. [Treatment of ulcerative colitis and Crohn's disease with monoclonal antibody].
    Asakura H.
    Nihon Rinsho; 2002 Mar; 60(3):531-8. PubMed ID: 11904969
    [Abstract] [Full Text] [Related]

  • 2. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease.
    Sartor RB.
    Gastroenterol Clin North Am; 1995 Sep; 24(3):475-507. PubMed ID: 8809232
    [Abstract] [Full Text] [Related]

  • 3. [Ulcerative colitis and Crohn's disease].
    Matsuoka K, Hibi T.
    Nihon Rinsho; 2005 May; 63 Suppl 5():507-11. PubMed ID: 15954400
    [No Abstract] [Full Text] [Related]

  • 4. Monoclonal antibody therapy of inflammatory bowel disease.
    van Deventer SJ, Camoglio L.
    Aliment Pharmacol Ther; 1996 May; 10 Suppl 2():107-11; discussion 112. PubMed ID: 8899109
    [Abstract] [Full Text] [Related]

  • 5. Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis.
    Niederau C, Backmerhoff F, Schumacher B, Niederau C.
    Hepatogastroenterology; 1997 May; 44(13):90-107. PubMed ID: 9058126
    [Abstract] [Full Text] [Related]

  • 6. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease.
    Schinzari F, Armuzzi A, De Pascalis B, Mores N, Tesauro M, Melina D, Cardillo C.
    Clin Pharmacol Ther; 2008 Jan; 83(1):70-6. PubMed ID: 17507924
    [Abstract] [Full Text] [Related]

  • 7. Antibodies to tumor necrosis factor-alpha in the treatment of Crohn's disease.
    Brown SJ, Abreu MT.
    Curr Opin Drug Discov Devel; 2005 Mar; 8(2):160-8. PubMed ID: 15782540
    [Abstract] [Full Text] [Related]

  • 8. Mechanisms and efficacy of immunobiologic therapies for inflammatory bowel diseases.
    Ghosh N, Chaki R, Mandal V, Lin GD, Mandal SC.
    Int Rev Immunol; 2010 Mar; 29(1):4-37. PubMed ID: 20100080
    [Abstract] [Full Text] [Related]

  • 9. [Immunology in medical practice. IV. Inflammatory bowel diseases: pathogenic starting points for specific therapy].
    van Deventer SJ.
    Ned Tijdschr Geneeskd; 1997 Oct 11; 141(41):1956-9. PubMed ID: 9550744
    [Abstract] [Full Text] [Related]

  • 10. Immunosuppressive agents in the treatment of Crohn's disease and ulcerative colitis.
    Hibi T, Iwao Y, Yajima T, Inoue N, Ueno Y, Takaishi H, Watanabe M, Ishii H.
    J Gastroenterol; 1995 Nov 11; 30 Suppl 8():121-3. PubMed ID: 8563872
    [Abstract] [Full Text] [Related]

  • 11. Update on idiopathic colitides.
    Strobel S, Abreu MT.
    Curr Opin Gastroenterol; 2013 Jan 11; 29(1):60-5. PubMed ID: 23207597
    [Abstract] [Full Text] [Related]

  • 12. [Polymorphism of the microsatellites and tumor necrosis factor genes in chronic inflammatory bowel diseases].
    Heresbach D, Ababou A, Bourienne A, Alizadeh M, Quelvennec E, Pagenault M, Dabadie A, Berre NH, Campion JP, Launois B, Gosselin M, Genetet B, Bretagne JF, Semana G.
    Gastroenterol Clin Biol; 1997 Jan 11; 21(8-9):555-61. PubMed ID: 9587492
    [Abstract] [Full Text] [Related]

  • 13. Immunotherapy of Crohn's disease.
    van Montfrans C, Camoglio L, van Deventer SJ.
    Mediators Inflamm; 1998 Jan 11; 7(3):149-52. PubMed ID: 9705600
    [Abstract] [Full Text] [Related]

  • 14. [New therapy in inflammatory bowel disease (infliximab)].
    Yoshizawa S, Hibi T.
    Nihon Rinsho; 2008 Jul 11; 66(7):1279-85. PubMed ID: 18616118
    [Abstract] [Full Text] [Related]

  • 15. Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease.
    Brand S.
    Gut; 2009 Aug 11; 58(8):1152-67. PubMed ID: 19592695
    [Abstract] [Full Text] [Related]

  • 16. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab.
    Pierik M, Vermeire S, Steen KV, Joossens S, Claessens G, Vlietinck R, Rutgeerts P.
    Aliment Pharmacol Ther; 2004 Aug 01; 20(3):303-10. PubMed ID: 15274667
    [Abstract] [Full Text] [Related]

  • 17. Monoclonal antibody therapy of inflammatory bowel disease.
    van Deventer SJ, Camoglio L.
    Pharm World Sci; 1997 Apr 01; 19(2):55-9. PubMed ID: 9151342
    [Abstract] [Full Text] [Related]

  • 18. [Discussion of the article by Dr. J. Kocián: Crohn's disease and ulcerative colitis. Questions of risk factors, etiology and therapy of nonspecific intestinal inflammatory diseases].
    Kubát R.
    Vnitr Lek; 1998 May 01; 44(5):297. PubMed ID: 9820077
    [No Abstract] [Full Text] [Related]

  • 19. Anti-Saccharomyces cerevisiae mannan antibodies in inflammatory bowel disease: comparison of different assays and correlation with clinical features.
    Annese V, Piepoli A, Perri F, Lombardi G, Latiano A, Napolitano G, Corritore G, Vandewalle P, Poulain D, Colombel JF, Andriulli A.
    Aliment Pharmacol Ther; 2004 Nov 15; 20(10):1143-52. PubMed ID: 15569117
    [Abstract] [Full Text] [Related]

  • 20. Introduction and overview: recent advances in the immunotherapy of inflammatory bowel disease.
    Hibi T, Inoue N, Ogata H, Naganuma M.
    J Gastroenterol; 2003 Mar 15; 38 Suppl 15():36-42. PubMed ID: 12698869
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.